Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

brain

- PMLiVE

Exhibition Trends 2026: What Pharma Exhibitors Need to Know Now

Exhibitions remain one of the most powerful ways for pharmaceutical and life sciences organisations to connect, educate and build trust. Whether you're launching innovations, strengthening partnerships or showcasing research, the...

Apex Events and Exhibitions

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

Lilly launches global Alzheimer’s campaign with Julianne Moore

The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

- PMLiVE

GSK to explore link between Shingrix and dementia risk in new UK research collaboration

More than 55 million people worldwide are currently living with the neurodegenerative disease

- PMLiVE

UK drug repurposing study identifies several potential dementia treatments

An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

- PMLiVE

Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab

The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK

- PMLiVE

Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

- PMLiVE

Lancet Commission report identifies two new modifiable dementia risk factors

The new risk factors identified are untreated vision loss and high low-density lipoprotein

- PMLiVE

Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

- PMLiVE

NHS figures reveal record number of people in England being diagnosed with dementia

Around a third of people living with dementia in England have not received a diagnosis

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Alzheimer’s Research UK awards Scottish universities £100,000 for dementia research

The neurological condition affects more than 944,000 people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links